PROTAC IRAK4 degrader-1

• UNSPSC Description:

  PROTAC IRAK4 degrader-1 is a Cereblon-based PROTAC interleukin-1 receptor-associated kinase 4 (IRAK4) degrader extracted from patent US20190192668A1 Compound I-210, makes 20-50%, and >50% IRAK4 degradation at 0.01, 0.1, and 1 μM in OCI-LY-10 cells, respectively[1].

• Target Antigen:

  IRAK; PROTACs

• Type:

  Reference compound

• Related Pathways:

  Immunology/Inflammation;PROTAC

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/protac-irak4-degrader-1.html

• Purity:

  99.72

• Solubility:

  DMSO : 180 mg/mL (ultrasonic)

• Smiles:

  O=C(C1=CC=C(N2C=C(NC(C3=COC(C4=CC=NC(NCC5CC5)=C4)=N3)=O)C(C(F)(F)F)=N2)C=C1)NCCCN(C=N6)C=C6CNC7=C8C(C(N(C9C(NC(CC9)=O)=O)C8=O)=O)=CC=C7

• Molecular Weight:

  904.85

• References & Citations:

  [1]Nello Mainolfi, et al. Irak degraders and uses thereof. US20190192668A1.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C (Powder, sealed storage, away from moisture)

• Clinical Information:

  No Development Reported

• CAS Number:

  2360533-90-8